3. Germline breast cancer susceptibility gene mutation (gBRCAMut) related efficacy. OC, ovarian cancer; BC, breast cancer; all mutation in clinically important was pathogenic, unless patients No. 02017 was likely pathogenic, 02021 and 02025 were benign, but both had pathogenic somatic BRCAMut. According to American College of Medical Genetics (ACMG) Standards and Guidelines.
